Knockdown of mTOR by lentivirusmediated RNA interference suppresses atherosclerosis and stabilizes plaques via a

Xiaochuang Wang1, Lingxia Li, Manxiang Li

  • 1Department of Emergency Medicine, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.

Insights

RNA interference targeting mammalian target of rapamycin (mTOR) effectively stabilized atherosclerotic plaques. This treatment reduced plaque size and improved fibrous cap thickness by increasing macrophage autophagy.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Genetics

Background:

  • Atherosclerotic plaque rupture causes acute coronary syndromes, a leading global health issue.
  • Current treatments for atherosclerosis are limited, highlighting the need for novel therapeutic strategies.
  • Mammalian target of rapamycin (mTOR) is implicated in atherosclerotic plaque development and is a potential therapeutic target.

Purpose of the Study:

  • To investigate the efficacy of in vivo RNA interference (RNAi) targeting mTOR using lentiviral (LV)-mediated small hairpin RNA (shRNA) in inhibiting atherosclerotic plaque progression.
  • To assess the impact of mTOR silencing on plaque stability, lipid metabolism, and macrophage content in a mouse model of atherosclerosis.

Main Methods:

  • Lentiviral vectors expressing shRNA against mTOR (LV-shmTOR) or a non-specific control (LV-shCON) were developed.
  • Atherosclerosis was induced in apolipoprotein E-deficient mice via high-fat diet and carotid artery constriction.
  • Mice received LV-shmTOR, LV-shCON, or phosphate-buffered saline treatment, followed by analysis of atherosclerotic plaques.

Main Results:

  • LV-mediated mTOR silencing significantly reduced mTOR mRNA and protein levels.
  • mTOR knockdown ameliorated dyslipidemia, decreased plaque area, and increased fibrous cap thickness, stabilizing plaques.
  • Silencing mTOR decreased macrophage infiltration and promoted autophagy, indicated by increased Atg13 dephosphorylation and LC3-I/LC3-II ratios.
  • Genes associated with plaque instability (MMP2, MCP-1, TF) were downregulated.

Conclusions:

  • LV-mediated mTOR silencing via RNAi is a promising therapeutic strategy for treating atherosclerotic plaques.
  • This approach stabilizes plaques by inducing macrophage autophagy and downregulating pro-inflammatory and matrix-degrading factors.
  • Targeting mTOR offers a potential new avenue for managing cardiovascular disease caused by atherosclerosis.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inflammation01:38

Inflammation

Overview
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...